<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Noxopharm Ltd. — News on 6ix</title>
<link>https://6ix.com/company/noxopharm-ltd</link>
<description>Latest news and press releases for Noxopharm Ltd. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 19 May 2026 23:42:06 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/noxopharm-ltd" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6836687d78dffbe2df15ebdf.webp</url>
<title>Noxopharm Ltd.</title>
<link>https://6ix.com/company/noxopharm-ltd</link>
</image>
<item>
<title>Noxopharms Sofra assets to be presented at global conference</title>
<link>https://6ix.com/company/noxopharm-ltd/news/noxopharms-sofra-assets-to-be-presented-at-global-conference</link>
<guid isPermaLink="true">https://6ix.com/company/noxopharm-ltd/news/noxopharms-sofra-assets-to-be-presented-at-global-conference</guid>
<pubDate>Tue, 19 May 2026 23:42:06 GMT</pubDate>
<description>Noxopharms Sofra assets to be presented at global conference</description>
</item>
<item>
<title>Noxopharm progresses US regulatory strategy</title>
<link>https://6ix.com/company/noxopharm-ltd/news/noxopharm-progresses-us-regulatory-strategy</link>
<guid isPermaLink="true">https://6ix.com/company/noxopharm-ltd/news/noxopharm-progresses-us-regulatory-strategy</guid>
<pubDate>Wed, 06 May 2026 02:35:59 GMT</pubDate>
<description>Noxopharm progresses US regulatory strategy</description>
</item>
<item>
<title>New data shows SOF-SKN active ingredient efficacy</title>
<link>https://6ix.com/company/noxopharm-ltd/news/new-data-shows-sof-skn-active-ingredient-efficacy</link>
<guid isPermaLink="true">https://6ix.com/company/noxopharm-ltd/news/new-data-shows-sof-skn-active-ingredient-efficacy</guid>
<pubDate>Fri, 01 May 2026 03:28:15 GMT</pubDate>
<description>New data shows SOF-SKN active ingredient efficacy</description>
</item>
<item>
<title>Innovative collaboration further expands Sofra platform</title>
<link>https://6ix.com/company/noxopharm-ltd/news/innovative-collaboration-further-expands-sofra-platform</link>
<guid isPermaLink="true">https://6ix.com/company/noxopharm-ltd/news/innovative-collaboration-further-expands-sofra-platform</guid>
<pubDate>Mon, 27 Apr 2026 02:42:05 GMT</pubDate>
<description>Innovative collaboration further expands Sofra platform</description>
</item>
<item>
<title>March 2026 Quarterly Activities Report and Appendix 4C</title>
<link>https://6ix.com/company/noxopharm-ltd/news/march-2026-quarterly-activities-report-and-appendix-4c-2</link>
<guid isPermaLink="true">https://6ix.com/company/noxopharm-ltd/news/march-2026-quarterly-activities-report-and-appendix-4c-2</guid>
<pubDate>Fri, 24 Apr 2026 03:44:14 GMT</pubDate>
<description>March 2026 Quarterly Activities Report and Appendix 4C</description>
</item>
<item>
<title>Positive SOF-SKN dosing data shows prolonged skin retention</title>
<link>https://6ix.com/company/noxopharm-ltd/news/positive-sof-skn-dosing-data-shows-prolonged-skin-retention</link>
<guid isPermaLink="true">https://6ix.com/company/noxopharm-ltd/news/positive-sof-skn-dosing-data-shows-prolonged-skin-retention</guid>
<pubDate>Wed, 22 Apr 2026 02:56:05 GMT</pubDate>
<description>Positive SOF-SKN dosing data shows prolonged skin retention</description>
</item>
<item>
<title>Noxopharm appoints Dr Olivier Laczka as new CEO</title>
<link>https://6ix.com/company/noxopharm-ltd/news/noxopharm-appoints-dr-olivier-laczka-as-new-ceo</link>
<guid isPermaLink="true">https://6ix.com/company/noxopharm-ltd/news/noxopharm-appoints-dr-olivier-laczka-as-new-ceo</guid>
<pubDate>Wed, 15 Apr 2026 03:48:14 GMT</pubDate>
<description>Noxopharm appoints Dr Olivier Laczka as new CEO</description>
</item>
<item>
<title>Resignation of Chief Executive Officer</title>
<link>https://6ix.com/company/noxopharm-ltd/news/resignation-of-chief-executive-officer-15</link>
<guid isPermaLink="true">https://6ix.com/company/noxopharm-ltd/news/resignation-of-chief-executive-officer-15</guid>
<pubDate>Tue, 14 Apr 2026 04:16:04 GMT</pubDate>
<description>Resignation of Chief Executive Officer</description>
</item>
<item>
<title>Appendix 4D and FY2026 Half Year Financial Report</title>
<link>https://6ix.com/company/noxopharm-ltd/news/appendix-4d-and-fy2026-half-year-financial-report</link>
<guid isPermaLink="true">https://6ix.com/company/noxopharm-ltd/news/appendix-4d-and-fy2026-half-year-financial-report</guid>
<pubDate>Fri, 27 Feb 2026 08:01:03 GMT</pubDate>
<description>Appendix 4D and FY2026 Half Year Financial Report</description>
</item>
<item>
<title>R&D rebate strengthens cash position</title>
<link>https://6ix.com/company/noxopharm-ltd/news/randd-rebate-strengthens-cash-position</link>
<guid isPermaLink="true">https://6ix.com/company/noxopharm-ltd/news/randd-rebate-strengthens-cash-position</guid>
<pubDate>Fri, 27 Feb 2026 03:55:11 GMT</pubDate>
<description>R&D rebate strengthens cash position</description>
</item>
<item>
<title>At-the-Market (ATM) agreement with Acuity Capital</title>
<link>https://6ix.com/company/noxopharm-ltd/news/at-the-market-atm-agreement-with-acuity-capital</link>
<guid isPermaLink="true">https://6ix.com/company/noxopharm-ltd/news/at-the-market-atm-agreement-with-acuity-capital</guid>
<pubDate>Fri, 27 Feb 2026 03:27:08 GMT</pubDate>
<description>At-the-Market (ATM) agreement with Acuity Capital</description>
</item>
<item>
<title>Sofra breakthrough science publish in major medical journal</title>
<link>https://6ix.com/company/noxopharm-ltd/news/sofra-breakthrough-science-publish-in-major-medical-journal</link>
<guid isPermaLink="true">https://6ix.com/company/noxopharm-ltd/news/sofra-breakthrough-science-publish-in-major-medical-journal</guid>
<pubDate>Wed, 11 Feb 2026 02:38:23 GMT</pubDate>
<description>Sofra breakthrough science publish in major medical journal</description>
</item>
<item>
<title>December 2025 Quarterly Activities Report and Appendix 4C</title>
<link>https://6ix.com/company/noxopharm-ltd/news/december-2025-quarterly-activities-report-and-appendix-4c-2</link>
<guid isPermaLink="true">https://6ix.com/company/noxopharm-ltd/news/december-2025-quarterly-activities-report-and-appendix-4c-2</guid>
<pubDate>Fri, 30 Jan 2026 03:29:26 GMT</pubDate>
<description>December 2025 Quarterly Activities Report and Appendix 4C</description>
</item>
<item>
<title>HERACLES clinical trial successfully completed</title>
<link>https://6ix.com/company/noxopharm-ltd/news/heracles-clinical-trial-successfully-completed</link>
<guid isPermaLink="true">https://6ix.com/company/noxopharm-ltd/news/heracles-clinical-trial-successfully-completed</guid>
<pubDate>Wed, 21 Jan 2026 03:21:05 GMT</pubDate>
<description>HERACLES clinical trial successfully completed</description>
</item>
<item>
<title>HERACLES clinical trial Update 5</title>
<link>https://6ix.com/company/noxopharm-ltd/news/heracles-clinical-trial-update-5</link>
<guid isPermaLink="true">https://6ix.com/company/noxopharm-ltd/news/heracles-clinical-trial-update-5</guid>
<pubDate>Wed, 03 Dec 2025 02:42:11 GMT</pubDate>
<description>HERACLES clinical trial Update 5</description>
</item>
<item>
<title>First dose in HERACLES clinical trial Part Two</title>
<link>https://6ix.com/company/noxopharm-ltd/news/first-dose-in-heracles-clinical-trial-part-two</link>
<guid isPermaLink="true">https://6ix.com/company/noxopharm-ltd/news/first-dose-in-heracles-clinical-trial-part-two</guid>
<pubDate>Mon, 17 Nov 2025 02:48:16 GMT</pubDate>
<description>First dose in HERACLES clinical trial Part Two</description>
</item>
<item>
<title>Second part of HERACLES clinical trial begins</title>
<link>https://6ix.com/company/noxopharm-ltd/news/second-part-of-heracles-clinical-trial-begins</link>
<guid isPermaLink="true">https://6ix.com/company/noxopharm-ltd/news/second-part-of-heracles-clinical-trial-begins</guid>
<pubDate>Wed, 05 Nov 2025 03:12:05 GMT</pubDate>
<description>Second part of HERACLES clinical trial begins</description>
</item>
<item>
<title>September 2025 Quarterly Activities Report and Appendix 4C</title>
<link>https://6ix.com/company/noxopharm-ltd/news/september-2025-quarterly-activities-report-and-appendix-4c-2</link>
<guid isPermaLink="true">https://6ix.com/company/noxopharm-ltd/news/september-2025-quarterly-activities-report-and-appendix-4c-2</guid>
<pubDate>Thu, 30 Oct 2025 02:18:18 GMT</pubDate>
<description>September 2025 Quarterly Activities Report and Appendix 4C</description>
</item>
<item>
<title>First US patent for Sofra technology platform</title>
<link>https://6ix.com/company/noxopharm-ltd/news/first-us-patent-for-sofra-technology-platform</link>
<guid isPermaLink="true">https://6ix.com/company/noxopharm-ltd/news/first-us-patent-for-sofra-technology-platform</guid>
<pubDate>Wed, 22 Oct 2025 01:46:07 GMT</pubDate>
<description>First US patent for Sofra technology platform</description>
</item>
<item>
<title>Extension of Convertible Notes and Funding</title>
<link>https://6ix.com/company/noxopharm-ltd/news/extension-of-convertible-notes-and-funding</link>
<guid isPermaLink="true">https://6ix.com/company/noxopharm-ltd/news/extension-of-convertible-notes-and-funding</guid>
<pubDate>Tue, 23 Sep 2025 02:49:33 GMT</pubDate>
<description>Extension of Convertible Notes and Funding</description>
</item>
</channel>
</rss>